The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTarget Healthc. Regulatory News (THRL)

Share Price Information for Target Healthc. (THRL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.30
Bid: 82.00
Ask: 82.30
Change: 1.30 (1.60%)
Spread: 0.30 (0.366%)
Open: 81.50
High: 82.60
Low: 81.20
Prev. Close: 81.00
THRL Live PriceLast checked at -
Target Healthcare REIT is an Investment Trust

To provide ordinary shareholders with an attractive level of income with the potential for capital and income growth from investing in best-in-class care home assets with attractive financial characteristics.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Initial Issue

26 Feb 2021 07:00

RNS Number : 4294Q
Target Healthcare REIT PLC
26 February 2021
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION IN PARTICULAR THE UNITED STATES, ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA (OTHER THAN TO PROFESSIONAL INVESTORS IN THE REPUBLIC OF IRELAND OR THE NETHERLANDS), CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND AND JAPAN.

THIS ANNOUNCEMENT HAS BEEN DETERMINED TO CONTAIN INSIDE INFORMATION FOR THE PURPOSES OF THE UK VERSION OF MARKET ABUSE REGULATION (EU) NO. 596/2014, WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

26 February 2021

 

TARGET HEALTHCARE REIT PLC

("Target" or the "Company", together with its subsidiaries, the "Group")

Results of Initial Issue

The Board of Directors of the Company is pleased to announce that it has successfully raised gross proceeds of £60 million through an oversubscribed issue of 54,054,054 Ordinary Shares ("New Shares") by way of an Initial Placing, Intermediaries Offer and Offer for Subscription (the "Initial Issue").

After careful consideration of the strong level of support and quality of demand from investors in the Initial Issue alongside the pipeline of suitable investment properties available, the Board determined to increase the size of the Initial Issue from £50 million to £60 million. Notwithstanding the increased number of New Shares made available pursuant to the Initial Issue, investor demand still exceeded the gross proceeds targeted and as such a scaling back exercise has been undertaken.

The Company has received valid acceptances under the Offer for Subscription from investors in respect of 4,900,304 New Shares and a further 1,251,300 New Shares under the Intermediaries Offer. In addition, a total of 47,902,450 New Shares were taken up pursuant to the Initial Placing.

 

The Initial Issue is conditional, amongst other things, upon the passing of the Resolutions at the General Meeting to be held at 12.00 p.m. on 1 March 2021, Admission of the Ordinary Shares occurring no later than 8.00 a.m. on 3 March 2021 (or such later time and/or date as the Company, Stifel Nicolaus Europe Limited ("Stifel") and Dickson Minto W.S. ("Dickson Minto" or "DM") may agree) and the Placing Agreement not being terminated and becoming unconditional in accordance with its terms.

Admission

 

Applications will be made in respect of the 54,054,054 New Shares to be issued pursuant to the Initial Issue to be admitted to the premium segment of the Official List and to trading on the London Stock Exchange's Main Market for listed securities ("Admission"). It is expected that Admission will become effective and dealings in the New Shares will commence on 3 March 2021. When issued, the New Shares will rank pari passu with the existing Ordinary Shares, including the right to receive all future dividends and distributions declared, made or paid after Admission.

Total Voting Rights

Following Admission, the Company will have 511,541,694 Ordinary Shares in issue. The total number of voting rights of the Company will be 511,541,694 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The New Shares will be issued in registered form and may be held in uncertificated form. The New Shares allocated will be issued through the CREST system unless otherwise stated. The New Shares will be eligible for settlement through CREST with effect from Admission.

 

Malcolm Naish, Chairman of the Company, said: 

"We are very pleased to have completed this oversubscribed equity raise and would like to thank all our investors for their ongoing support. Given the challenges that our sector has faced over the past 12 months, this is a strong endorsement of the Company's investment case, purpose and outlook as we emerge from this pandemic and resume the careful expansion of the portfolio in line with our stringent investment strategy."

 

Dealing codes for the Ordinary Shares and the New Shares

Ticker: THRL

ISIN for the New Shares: GB00BJGTLF51

SEDOL for the New Shares: BJGTLF5

The Company's LEI: 213800RXPY9WULUSBC04

 

Enquiries:

 

 Target Fund Managers Limited (Investment Manager to the Company)

Kenneth MacKenzie

 

+44 1786 845 912

Gordon Bland

 

+44 1786 845 912

 

 

 

Stifel Nicolaus Europe Limited

 

 

Mark Young

mark.young@stifel.com

+44 20 7710 7600

Mark Bloomfield

mark.bloomfield@stifel.com

+44 20 7710 7600

Rajpal Padam

rajpal.padam@stifel.com

+44 20 7710 7600

 

 

 

FTI Consulting

 

 

Dido Laurimore

TargetHealthcare@fticonsulting.com

+44 20 3727 1000

Claire Turvey

 

 

Richard Gotla

 

 

    

 

 

Capitalised terms used and not otherwise defined in this announcement have the meaning given to them in the Prospectus.

 

 

Important Information

 

The person responsible for arranging for the release of this announcement on behalf of Target Healthcare REIT plc is Kenneth MacKenzie, Founder and Chief Executive of Target Fund Managers Limited.

 

The information contained in this announcement is given at the date of its publication (unless otherwise marked) and is subject to updating, revision and amendment from time to time.

 

This announcement does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States. The New Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") or under any securities laws of any state or other jurisdiction of the United States and may not be offered, sold, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, within the United States except pursuant to an applicable exemption from or in a transaction not subject to the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There will be no public offer of the New Shares in the United States.

 

This announcement is for information purposes only and is not intended to and does not constitute or form part of any offer or invitation to purchase or subscribe for, or any solicitation to purchase or subscribe for, any securities in any jurisdiction. No offer or invitation to purchase or subscribe for, or any solicitation to purchase or subscribe for, any securities will be made in any jurisdiction in which such an offer or solicitation is unlawful. The information contained in this announcement is not for release, publication or distribution to persons in the United States, any member state of the EEA (other than to professional investors in the Republic of Ireland or the Netherlands) Canada, Australia, the Republic of South Africa, New Zealand or Japan, and should not be distributed, forwarded to or transmitted in or into any jurisdiction, where to do so might constitute a violation of local securities laws or regulations.

 

Stifel, which is authorised and regulated by the Financial Conduct Authority, is acting exclusively for the Company in connection with the matters described in this announcement and is not acting for or advising any other person, or treating any other person as its client, in relation thereto and will not be responsible for providing the regulatory protection afforded to clients of Stifel or advice to any other person in relation to the matters contained herein.

 

Dickson Minto, which is authorised and regulated by the Financial Conduct Authority, is acting exclusively for the Company in connection with the matters described in this announcement and is not acting for or advising any other person, or treating any other person as its client, in relation thereto and will not be responsible for providing the regulatory protection afforded to clients of Dickson Minto or advice to any other person in relation to the matters contained herein.

 

This announcement may include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology. All statements other than statements of historical facts included in this announcement, including, without limitation, those regarding the Company's financial position, strategy, plans, proposed acquisitions and objectives, are forward-looking statements.

 

Forward-looking statements are subject to risks and uncertainties and, accordingly, the Company's actual future financial results and operational performance may differ materially from the results and performance expressed in, or implied by, the statements. These forward-looking statements speak only as at the date of this announcement and cannot be relied upon as a guide to future performance. The Company, Target Fund Managers Limited, DM and Stifel expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the assumptions, conditions or circumstances on which any such statements are based unless required to do so by the Financial Services and Markets Act 2000, the Prospectus Regulation Rules of the Financial Conduct Authority or other applicable laws, regulations or rules.

 

None of the Company, Target Fund Managers Limited, Stifel, Dickson Minto or any of their respective affiliates, accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to this announcement, including the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith. The Company, Target Fund Managers Limited, Stifel, Dickson Minto and their respective affiliates, accordingly disclaim all and any liability whether arising in tort, contract or otherwise which they might otherwise have in respect of this announcement or its contents or otherwise arising in connection therewith.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEDKPBBDBKBCBB
Date   Source Headline
9th May 20247:00 amRNSNet Asset Value, Corporate Update & Dividend
28th Mar 20242:30 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSHalf-year Report
8th Mar 20249:00 amRNSInvestor Presentation via Investor Meet Company
22nd Feb 20247:00 amRNSNotice of Half Year Results
6th Feb 20242:00 pmEQSEdison issues update on Target Healthcare REIT (THRL): Rent cover at a high and fully covered DPS
1st Feb 20247:00 amRNSNet Asset Value, Corporate Update & Dividend
30th Nov 20237:00 amRNSResult of AGM
7th Nov 202310:16 amEQSEdison issues outlook on Target Healthcare REIT (THRL): DPS growth from a sustainable base
1st Nov 20237:00 amRNSNet Asset Value, Corporate Update & Dividend
31st Oct 20235:30 pmRNSAnnual Financial Report
10th Oct 20237:00 amRNSFinal Results
4th Oct 20232:00 pmRNSNotice of Full Year Results
11th Aug 20238:09 amRNSEdison issues update on Target Healthcare REIT
2nd Aug 20237:00 amRNSNet Asset Value, Corporate Update & Dividend
3rd May 20237:00 amRNSNet Asset Value, Corporate Update & Dividend
28th Mar 202311:37 amRNSDirector/PDMR Shareholding
27th Mar 20237:00 amRNSHalf-year Report
27th Mar 20237:00 amRNSDisposal of four care homes in Northern Ireland
23rd Mar 20237:00 amRNSNotice of Half Year Results
17th Feb 202311:08 amRNSHolding(s) in Company
2nd Feb 20237:00 amRNSNet Asset Value, Corporate Update & Dividend
7th Dec 20227:00 amRNSDirectorate Change
6th Dec 20222:30 pmRNSResult of AGM
21st Nov 20225:07 pmRNSHolding(s) in Company
21st Nov 20227:00 amRNSHolding(s) in Company
21st Nov 20227:00 amRNSHolding(s) in Company
8th Nov 20225:47 pmRNSAnnual Financial Report
2nd Nov 20227:00 amRNSNet Asset Value, Corporate Update & Dividend
28th Oct 20229:17 amRNSHolding(s) in Company
17th Oct 20229:20 amRNSHolding(s) in Company
12th Oct 20227:00 amRNSFinal Results
12th Oct 20227:00 amRNSDirectorate Change
1st Sep 20227:00 amRNSPortfolio Update
4th Aug 20227:00 amRNSNet Asset Value, Corporate Update & Dividend
22nd Jun 20227:00 amRNSHolding(s) in Company
9th Jun 20226:01 pmRNSHolding(s) in Company
9th Jun 20227:00 amRNSInclusion in FTSE 250 Index
6th Jun 20229:42 amRNSHolding(s) in Company
9th May 202211:43 amRNSDirector/PDMR Shareholding
5th May 202210:01 amRNSHolding(s) in Company
5th May 20227:00 amRNSNet Asset Value, Corporate Update & Dividend
3rd May 20229:21 amRNSHolding(s) in Company
16th Mar 20227:00 amRNSHalf-year Report
10th Mar 20227:00 amRNSNotice of Half Year Results
1st Feb 20227:00 amRNSDirectorate Change
27th Jan 20227:00 amRNSNet Asset Value, Corporate Update & Dividend
20th Dec 20217:00 amRNSCompletion of Portfolio Acquisition
15th Dec 20217:00 amRNSResult of AGM
30th Nov 20217:00 amRNSNew long-term institutional debt facility

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.